Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Dyslipidemia Pipeline Review, H2 2016 - 61 Companies & 127 Molecules - Research and Markets

Research and Markets
Posted on: 03 Oct 16

Research and Markets has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2016" report to their offering.

Dyslipidemia pipeline therapeutics constitutes close to 127 molecules, out of which approximately 111 molecules are developed by Companies and the remaining by the Universities/Institutes.

Dyslipidemia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood, such as genetic predisposition, diet, age and gender, and type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 19, 17, 15, 3, 45, 5 and 3, respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 14 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Dyslipidemia Overview
  3. Therapeutics Development
  4. Pipeline Products for Dyslipidemia - Overview
  5. Pipeline Products for Dyslipidemia - Comparative Analysis
  6. Dyslipidemia - Therapeutics under Development by Companies
  7. Dyslipidemia - Therapeutics under Investigation by Universities/Institutes
  8. Dyslipidemia Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. Dyslipidemia - Products under Development by Companies
  13. Dyslipidemia - Products under Investigation by Universities/Institutes
  14. Dyslipidemia - Companies Involved in Therapeutics Development
  • Acasti Pharma Inc.
  • AFFiRiS AG
  • AstraZeneca Plc
  • BCWorld Pharm Co. Ltd.
  • BioRestorative Therapies, Inc.
  • Cadila Pharmaceuticals Limited
  • Cardax, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • Debiopharm International SA
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • Gemphire Therapeutics Inc.
  • GlaxoSmithKline Plc
  • Golden Biotechnology Corp.
  • HanAll Biopharma Co., Ltd.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Huons Co., Ltd.
  • Hyundai Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • IPCA Laboratories Limited
  • Jeil Pharmaceutical Co., Ltd.
  • Lipicard Technologies Limited
  • Lipigon Pharmaceuticals AB
  • LipimetiX Development Inc.
  • Lotus Pharmaceutical Co., Ltd.
  • Matinas BioPharma Holdings, Inc.
  • Merck & Co., Inc.
  • Nimbus Therapeutics, LLC
  • Nippon Chemiphar Co., Ltd.
  • Omeros Corporation
  • Pfizer Inc.
  • Thetis Pharmaceuticals LLC
  • Torrent Pharmaceuticals Limited

For more information about this report visit

View source version on

Business Wire

Last updated on: 03/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.